So the Fast Track 2 trial is a trans-Tasman Radiation Oncology Group collaborative trial that was run through Australia in collaboration with ANZUP through the region. It recruited in seven centres in Australia and one centre in New Zealand with 70 patients recruited. This is the long-term and final analysis that we’re presenting at ESTRO at this meeting. The results show that at an average follow-up of five years, with the maximum there were still patients at risk at 84 months after follow-up, that the local control rate was 100%...
So the Fast Track 2 trial is a trans-Tasman Radiation Oncology Group collaborative trial that was run through Australia in collaboration with ANZUP through the region. It recruited in seven centres in Australia and one centre in New Zealand with 70 patients recruited. This is the long-term and final analysis that we’re presenting at ESTRO at this meeting. The results show that at an average follow-up of five years, with the maximum there were still patients at risk at 84 months after follow-up, that the local control rate was 100%. So in other words there were no cancer occurrences in the treated kidney and there were no patients who died from their cancer either. So the cancer-specific survival was 100%. Importantly, we noticed that there was no late adverse event that was demonstrated from our prior analysis some two years ago. We had seven patients out of that 70 that had grade three adverse events, and that meant there was a 10% grade three adverse event rate. There was no grade four or grade 5 very severe adverse event rate. And most of these were transient nausea and vomiting and some flank pain as well. These all happened within nine months of the actual treatment. And so when we had this longer-term follow-up, importantly, there wasn’t any long-term complication that we were not expecting to see that were down the track. So we try to compare this to surgery. So surgery is still the standard of care for primary kidney cancer. The patients that were enrolled in this trial had cancers that were aggressive and growing and perhaps growing after initial surveillance but were patients that were not suited for surgery. In other words, they had technically high-risk cancers that might need a radical nephrectomy in patients who had already had prior kidney disease, or there were patients who had other medical comorbidities that meant that surgery was potentially risky, or even some patients that declined surgery altogether. And so this was not a population that would, on average, receive surgery. But when we look at these outcomes, they’re really quite exceptional, and having the control rates as good as they are at this long-term follow-up means that potentially we should be testing this kind of approach in future trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
